Shenzhen Kangtai Biological Products (300601.SZ): Application for clinical trial of adsorbed acellular pertussis (components) combined vaccine (for adults, teenagers, and children) has been accepted.
Kangtai Biological (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biological Technology Co., Ltd. (Minhai Biological), received a acceptance notification from the National Medical Products Administration today, approving the clinical trial application for the research and development of a combined adsorbed acellular pertussis (component) vaccine for adults, adolescents, and children.
Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biological Technology Co., Ltd. (referred to as "Minhai Biological"), received a notice of acceptance issued by the National Medical Products Administration today, allowing the acceptance of Minhai Biological's clinical trial application for the research and development of an adsorbed acellular pertussis (component) combined vaccine (for adults, adolescents, and children).
Related Articles
HKBN (01310): Restore public shareholding ratio
On January 9th, SSY GROUP (02005) spent 1.387 million Hong Kong dollars to repurchase 456,000 shares.
CIFI HOLD GP (00884) cumulative contract sales amount approximately 16.1 billion yuan in 2025.
HKBN (01310): Restore public shareholding ratio
On January 9th, SSY GROUP (02005) spent 1.387 million Hong Kong dollars to repurchase 456,000 shares.
CIFI HOLD GP (00884) cumulative contract sales amount approximately 16.1 billion yuan in 2025.
RECOMMEND
Bank Of America Sees Three Drivers Supporting Chinese Consumer Stocks: Low Base, Deep Undervaluation, And Convertible‑Like Defensive Traits
07/01/2026
Cross‑Border E‑Commerce In 2025: Tariffs, Trade Wars, And Shifting Away From The United States
07/01/2026
Asian Stock Markets Record The Strongest Annual Start Ever As Shanghai Composite Hits Multi‑Year High And Sets Longest Winning Streak; Japan And Korea Rally
07/01/2026
